Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. Tsakok T, et al. Among authors: murphy r. JAMA Dermatol. 2019 Nov 1;155(11):1235-1243. doi: 10.1001/jamadermatol.2019.1783. JAMA Dermatol. 2019. PMID: 31532460 Free PMC article.
UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.
Craig FF, Thomas KS, Mitchell EJ, Williams HC, Norrie J, Mason JM, Ormerod AD; UK Dermatology Clinical Trials Network’s STOP GAP Trial Team. Craig FF, et al. Trials. 2012 Apr 28;13:51. doi: 10.1186/1745-6215-13-51. Trials. 2012. PMID: 22540770 Free PMC article. Clinical Trial.
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools.
Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Coates LC, et al. Among authors: murphy r. Arthritis Care Res (Hoboken). 2014 Sep;66(9):1410-6. doi: 10.1002/acr.22284. Arthritis Care Res (Hoboken). 2014. PMID: 24470406 Free article.
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis.
Yiu ZZN, Exton LS, Jabbar-Lopez Z, Mohd Mustapa MF, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CEM, Smith CH, Warren RB. Yiu ZZN, et al. Among authors: murphy r. J Invest Dermatol. 2016 Aug;136(8):1584-1591. doi: 10.1016/j.jid.2016.03.035. Epub 2016 Apr 13. J Invest Dermatol. 2016. PMID: 27085754 Free PMC article. Review.
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Jabbar-Lopez ZK, et al. Among authors: murphy r. J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27. J Invest Dermatol. 2017. PMID: 28457908 Free PMC article. Review.
Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Jabbar-Lopez ZK, et al. Among authors: murphy r. J Invest Dermatol. 2017 Dec;137(12):2644-2646. doi: 10.1016/j.jid.2017.07.848. Epub 2017 Aug 31. J Invest Dermatol. 2017. PMID: 28864078 Free article. No abstract available.
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS; Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP). Bronckers IMGJ, et al. Among authors: murphy r. JAMA Dermatol. 2017 Nov 1;153(11):1147-1157. doi: 10.1001/jamadermatol.2017.3029. JAMA Dermatol. 2017. PMID: 28903160 Free PMC article.
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. Among authors: murphy r. J Invest Dermatol. 2018 Mar;138(3):534-541. doi: 10.1016/j.jid.2017.10.005. Epub 2017 Oct 17. J Invest Dermatol. 2018. PMID: 29054603 Free PMC article.
4,712 results